DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for autonomic nervous system disease — screening already-approved drugs against its 7-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAutonomic nervous system disease maps to a 7-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for autonomic nervous system disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
phosphoglycerate dehydrogenase (PHGDH) — PHGDH is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 1~{r}drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6RJ3 · 1.42 Å · ligand 4-[(1~{R})-1-[(2-methyl-5-phenyl-pyrazol-3-yl)carbonylamino]ethyl]benzoic acid (K58). Experimental structure, not a prediction.
What the evidence adds up to
No drug is tested for autonomic nervous system disease in these abstracts. The 2012 review describes autonomic drugs as agents that imitate or inhibit sympathetic and parasympathetic function, and notes that many other drug classes produce autonomic side effects, but it does not report any clinical trial data. The 2015 review states that available non-invasive tests for autonomic function are sparse and surrogate measures, and that new laboratory markers such as NPY and VIP assays are only a hope. The 1956 manual is criticised for evaluating therapy in terms of future hopes rather than observed experience, and the 1994 review of a textbook notes that autonomic disorders have received scant attention in mainstream medical education and publications.
No survival rates, response rates, or sample sizes appear in any of these abstracts. The 1956 book is explicitly judged as failing to present new material or well-established facts. The 2015 review confirms that direct assessment of autonomic activity is not yet possible in practice. There is no evidence of any drug being repurposed or tested for any autonomic nervous system disease.
What is still missing is any clinical trial that tests a specific drug in patients with a defined autonomic disorder, any patient stratification strategy, and any funding for such trials. The field lacks direct biomarkers and relies on indirect cardiovascular reflexes.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Anesthesia Progress · 2012 · 58 citations · open access
Basic and Clinical Pharmacology of Autonomic Drugs
AbstractAutonomic drugs are used clinically to either imitate or inhibit the normal functions of the sympathetic and parasympathetic nervous systems. A large number of additional drug classes also interact with these systems to produce a stunning number of possible side effects. This article reviews the basic function of the autonomic nervous system and the various drug classes that act within these neural synapses.
Journal of Pre-Clinical and Clinical Research · 2015 · 8 citations · open access
Current concepts in clinical and laboratory assessments of autonomic nervous system activity
AbstractAs the autonomic nervous system (ANS) dysfunction is present in course of many disorders, an objective assessment of the ANS function is very important. In practice, the assessment is difficult, and based rather on indirect analysis of autonomically-controlled cardiovascular reflexes, than on direct recording of activity of central or peripheral autonomic structures. The aim of our paper was to discuss briefly current, clinical and scientific ANS investigations, as well as possible future methods of autonomic activity evaluation. A brief description of the state of knowledge. The review presents a short outline of autonomic function assessments based on clinical autonomic tests (e.g. "Ewing's battery") and discusses the heart rate variability (HRV) study, as currently popular and widespread option of analysis of the ANS activity. Other, complementary methods, including the baroreceptor sensitivity testing, microneurography or plasma norepinephrine measurement were also mentioned. The article also provides premises related to the determination of selected neuropeptides in plasma or saliva as an innovative concept of autonomic activity assessment. Summary. The available, clinical, non-invasive methods used for assessment of the ANS function are still relatively sparse and, in fact, a surrogate for direct ANS assessment. New methods of autonomic tension determination are still needed that would allow a more complete and reliable assessment. Reports of potential new laboratory markers of the ANS activity (NPY and VIP assay) bring some hope.
Archives of Internal Medicine · 1956 · 1 citations · open access
Management of Disorders of the Autonomic Nervous System.
AbstractA therapeutic manual, to serve any useful purpose, should either present new material or present well-established facts better than they can be presented elsewhere. To cover the management of disorders of the autonomic nervous system in 186 pages is beyond the scope of most experts who devote their lives to the subject. It has not been accomplished here. The chapters on anatomy, physiology, and pharmacology are routine, and there is not enough space available for including important details. To some extent, therapy is evaluated in terms of future hopes rather than observed and critically analyzed experience. It is unfortunate but true that books as short as this make almost impossible demands on the author to achieve needed compression without loss of essential detail or to present new experiences without restriction merely to one view of a problem.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
